Blood Biomarkers Reflect the Effects of Obesity and Inflammation on the Human Breast Transcriptome. Academic Article uri icon

Overview

abstract

  • Obesity is a risk factor for the development of post-menopausal breast cancer. Breast white adipose tissue (WAT) inflammation, which is commonly found in women with excess body fat, is also associated with increased breast cancer risk. Both local and systemic effects are likely to be important for explaining the link between excess body fat, adipose inflammation and breast cancer. The first goal of this cross-sectional study of 196 women was to carry out transcriptome profiling to define the molecular changes that occur in the breast related to excess body fat and WAT inflammation. A second objective was to determine if commonly measured blood biomarkers of risk and prognosis reflect molecular changes in the breast. Breast WAT inflammation was assessed by immunohistochemistry. Bulk RNA-sequencing was carried out to assess gene expression in non-tumorous breast. Obesity and WAT inflammation were associated with a large number of differentially expressed genes and changes in multiple pathways linked to the development and progression of breast cancer. Altered pathways included inflammatory response, complement, KRAS signaling, TNFα signaling via NFкB, IL6-JAK-STAT3 signaling, epithelial mesenchymal transition, angiogenesis, interferon γ response, and TGF-β signaling. Increased expression of several drug targets such as aromatase, TGF-β1, IDO-1 and PD-1 were observed. Levels of various blood biomarkers including hsCRP, IL6, leptin, adiponectin, triglycerides, HDL cholesterol and insulin were altered and correlated with molecular changes in the breast. Collectively, this study helps to explain both the link between obesity and breast cancer and the utility of blood biomarkers for determining risk and prognosis.

publication date

  • July 27, 2021

Research

keywords

  • Breast Neoplasms
  • Inflammation
  • Obesity
  • Transcriptome

Identity

Digital Object Identifier (DOI)

  • 10.1093/carcin/bgab066

PubMed ID

  • 34314488